Accessibility Statement Skip Navigation
  • PRNewswire.com
  • Resources
  • +91 22-69790010
  • Client Login
  • Send a Release
PR Newswire: news distribution, targeting and monitoring
  • News
  • Products
  • Contact
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please use Advanced Search to search all press releases.
  • Overview
  • Distribution
  • Guaranteed Paid Placement
  • SocialBoost
  • Multichannel Amplification
  • All Products
  • Hamburger menu
  • PR Newswire: news distribution, targeting and monitoring
  • Send a Release
    • Telephone

    • +91 22-69790010 from 9 AM - 5:30 PM IST

    • Contact
    • Contact

      +91 22-69790010
      from 9 AM - 5:30 PM IST

  • Request More Information
  • Journalists
  • Request More Information
  • Journalists
  • Overview
  • Distribution by PR Newswire
  • Guaranteed Paid Placement
  • SocialBoost
  • Multichannel Amplification
  • All Products
  • Request More Information
  • Journalists
  • Request More Information
  • Journalists

ELONGATE Announces Title Sponsorship of EB Research Partnership's #VentureIntoCures Event
  • USA - English

ELONGATE Logo

News provided by

ELONGATE

05 Nov, 2021, 16:56 IST

Share this article

Share toX

Share this article

Share toX

ZUG, Switzerland, Nov. 5, 2021 /PRNewswire/ -- The world's biggest social impact focused crypto, Elongate, announces its title sponsorship of EB Research Partnership's #VentureIntoCures event on November 18. Announced officially on October 30, the second annual digital stream event will be hosted by actor and The Brother's Trust member, Tom Holland.

In line with this year's Epidermolysis Bullosa Awareness Week, Elongate and EB Research Partnership came together on The Balancing Act which aired October 26 on Lifetime TV to talk about the rare disorder and how it affects patients. Elongate's Chief Brand Officer, Alexander Gambon, and EB Research Partnership's CEO, Michael Hund, also talked about how the organizations' collaboration is accelerating initiatives to discover treatment options for Epidermolysis Bullosa (EB) through blockchain-powered social impact and charity. To celebrate the partnership, Elongate has committed US$50,000 in cryptocurrency matching funds to the #healEB program.

In May 2021, EB Research Partnership announced a US$150,000 seed donation from Elongate to launch the #CryptoForCures Fund, establishing Elongate as the Founding Member. Aiming to raise US$1,000,000 in cryptocurrency donations by the end of 2021, EBRP funds competitive research projects that study groundbreaking technologies such as gene editing, exon skipping, and stem cell therapies with the goal of curing EB by 2030.

EB affects approximately 500,000 people worldwide. Called "Butterfly Children" because their skin is as fragile as the wings of a butterfly, children with EB face severe pain, open external and internal wounds, and a grueling daily bandaging process. There is currently no treatment or cure for EB. However, EBRP's model is helping to fast-track not only therapies for EB, but for 7,000 rare diseases that affect 400 million people worldwide.

Details about this year's Venture Into Cures event can be found here: https://www.ventureintocures.org/

Logo - https://mma.prnewswire.com/media/1493177/ELONGATE_Logo.jpg

Related Links

https://www.elongate.cc/

Modal title

Contact PR Newswire

  • +91 22-69790010

Global Sites

  • APAC
  • APAC - Traditional Chinese
  • Asia
  • Brazil
  • Canada
  • Czech
  • Denmark
  • Finland
  • France
  • Germany

 

  • India
  • Indonesia
  • Israel
  • Italy
  • Mexico
  • Middle East
  • Middle East - Arabic
  • Netherlands
  • Norway
  • Poland

 

  • Portugal
  • Russia
  • Slovakia
  • Spain
  • Sweden
  • United Kingdom
  • United States

Do not sell or share my personal information:

  • Submit via [email protected] 
  • Call Privacy toll-free: 877-297-8921
Global Sites
  • Asia
  • Brazil
  • Canada
  • Czech
  • Denmark
  • Finland
  • France
  • Germany
  • India
  • Israel
  • Italy
  • Mexico
  • Middle East
  • Netherlands
  • Norway
  • Poland
  • Portugal
  • Russia
  • Slovakia
  • Spain
  • Sweden
  • United Kingdom
  • United States
+91 (0) 22 6169 6000
from 9 AM - 5:30 PM IST
  • Terms of Use
  • Privacy Policy
  • GDPR
  • Information Security Policy
  • Site Map
  • Cookie Settings
Copyright © 2025 Cision US Inc.